Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONTAK in Relapsed/Refractory B-Cell NHL
NCT00211276Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2005
- Primary completion
- Jan 2007
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denileukin diftitox in B-cell non-Hodgkin lymphoma, sponsored by Eisai Co., Ltd. Primary endpoint: Objective Response Rate. Started Mar 2005; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00211276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211276.